Announcements
- Pharming Group to participate in May investor conference
- Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
- Pharming Group reports first quarter 2024 financial results and provides business update
- Pharming Group to report first quarter 2024 financial results on May 8
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
- Pharming Group announces the placement of €100 million convertible bonds due 2029
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
- Pharming Group announces the 2024 Annual General Meeting of Shareholders
More ▼
Key statistics
As of last trade Pharming Group NV (PHGN:BER) traded at 0.852, 0.59% above its 52-week low of 0.847, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.852 |
---|---|
High | 0.852 |
Low | 0.852 |
Bid | 0.8365 |
Offer | 0.8465 |
Previous close | 0.8525 |
Average volume | 10.51k |
---|---|
Shares outstanding | 673.44m |
Free float | 657.75m |
P/E (TTM) | -- |
Market cap | 568.79m EUR |
EPS (TTM) | -0.016 EUR |
Data delayed at least 15 minutes, as of May 20 2024 07:10 BST.
More ▼